Charlotte Robinson

DocwireNews

The effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on renal outcomes in patients with different combinations of chronic kidney disease, heart failure, and type 2 diabetes have not been quantified. To address this gap, Tariq Jamal Siddiqi, MD, and colleagues queried the PubMed and Scopus databases through December 2023 for primary and secondary analyses of placebo-controlled trials of SGLT2i in such patients.&nbsp;&nbsp;The study outcomes were a composite kidney endpoint (combination of eGFR &lt;15 mL/min/1.73 m2, continuous doubling of serum creatinine, variable percentage change in eGFR, and need for kidney replacement therapy), rate of eGFR slope decline, and albuminuria progression. Hazard ratios and mean differences with 95% confidence intervals were extracted, and the results were pooled using a random-effect model through Review Manager.&nbsp;Analysis of 11 trials and 80,928 patients found that SGLT2i reduced the risk of the composite kidney endpoint by 41% (HR, 0.59; 95% CI, 0.42-0.83) in heart failure with reduced ejection fraction, 36% (HR, 0.64; 95% CI, 0.55-0.73) in CKD, and 38% (HR, 0.62; 95% CI, 0.56-0.69) in type 2 diabetes compared to the placebo. SGLT2i was similarly beneficial in combinations of the three comorbidities and in patients without heart failure, CKD, or type 2 diabetes at baseline.&nbsp;SGLT2i also reduced the risk of sustained doubling of serum creatinine by 36% (HR, 0.64; 95% CI, 0.56-0.72) and slowed the rate of eGFR slope decline in the overall population. A consistent positive effect on renal outcomes was observed in most subpopulations with available data.&nbsp;In conclusion, SGLT2i improved renal outcomes in patients with heart failure, CKD, and type 2 diabetes. The benefits were consistent among patients with different combinations of these comorbidities.&nbsp;Source: <a href="https://doi.org/10.1681/ASN.0000000000000491" target="_blank" rel="noopener">Journal of the American Society of Nephrology</a>.&nbsp;

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Effects of SGLT2i on Renal Outcomes Across Cardiovascular-Kidney-Metabolic Conditions 

Nephrology Times

Effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on renal outcomes in patients with chronic kidney disease (CKD), heart failure, and type 2 diabetes were examined.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe